61413-54-5 | 4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$9.00	$6.00
5mg	95%	in stock	$38.00	$27.00
10mg	95%	in stock	$70.00	$49.00
100mg	95%	in stock	$123.00	$86.00
250mg	95%	in stock	$208.00	$145.00
1g	95%	in stock	$549.00	$384.00
5g	95%	in stock	$1,948.00	$1,363.00

Description

• Catalog Number: AB47520
• Chemical Name: 4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one
• CAS Number: 61413-54-5
• Molecular Formula: C16H21NO3
• Molecular Weight: 275.3428
• MDL Number: MFCD00270906
• SMILES: COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1
• NSC Number: 760125

Computed Properties

• Complexity: 341
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1
• XLogP3: 2.2

Literature

• The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator.

  Toxicology and applied pharmacology 20160401

• Effects of lisdexamfetamine in a rat model of binge-eating.

  Journal of psychopharmacology (Oxford, England) 20151201

• Atrazine enhances progesterone production through activation of multiple signaling pathways in FSH-stimulated rat granulosa cells: evidence for premature luteinization.

  Biology of reproduction 20141101

• Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network.

  eLife 20140101

• Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells.

  The Biochemical journal 20130901

• Quercetin acutely relaxes airway smooth muscle and potentiates β-agonist-induced relaxation via dual phosphodiesterase inhibition of PLCβ and PDE4.

  American journal of physiology. Lung cellular and molecular physiology 20130901

• Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized guinea pigs.

  Advances in experimental medicine and biology 20130101

• Phosphodiesterase 4-targeted treatments for autoimmune diseases.

  BMC medicine 20130101

• Role of yessotoxin in calcium and cAMP-crosstalks in primary and K-562 human lymphocytes: the effect is mediated by anchor kinase A mitochondrial proteins.

  Journal of cellular biochemistry 20121201

• Phosphodiesterases as therapeutic targets for Alzheimer's disease.

  ACS chemical neuroscience 20121121

• Atrazine acts as an endocrine disrupter by inhibiting cAMP-specific phosphodiesterase-4.

  Toxicology and applied pharmacology 20121115

• Regio- and enantioselective palladium-catalyzed allylic alkylation of nitromethane with monosubstituted allyl substrates: synthesis of (R)-rolipram and (R)-baclofen.

  The Journal of organic chemistry 20121019

• Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder.

  Biological psychiatry 20121001

• Evaluating the significance of cyclic adenosine monophosphate-mediated signaling in human prostate: a functional and biochemical study.

  Urology 20121001

• Evidence for global reduction in brain cyclic adenosine monophosphate signaling in depression.

  Biological psychiatry 20121001

• Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

  Journal of the neurological sciences 20120915

• Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.

  Journal of medicinal chemistry 20120913

• Various phosphodiesterase activities in different regions of the heart alter the cardiac effects of nitric oxide.

  Journal of cardiovascular pharmacology 20120901

• Drug-eluting microfibrous patches for the local delivery of rolipram in spinal cord repair.

  Journal of controlled release : official journal of the Controlled Release Society 20120810

• Cyclic AMP increases COX-2 expression via mitogen-activated kinase in human myometrial cells.

  Journal of cellular and molecular medicine 20120701

• Working memory in the aged Ts65Dn mouse, a model for Down syndrome.

  Behavioural brain research 20120615

• Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA.

  Inflammatory bowel diseases 20120601

• Contribution of the extracellular cAMP-adenosine pathway to dual coupling of β2-adrenoceptors to Gs and Gi proteins in mouse skeletal muscle.

  The Journal of pharmacology and experimental therapeutics 20120601

• Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation.

  The Journal of physiology 20120601

• Attenuation by sphingosine-1-phosphate of rat microvessel acute permeability response to bradykinin is rapidly reversible.

  American journal of physiology. Heart and circulatory physiology 20120515

• Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.

  The Prostate 20120515

• Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.

  American journal of respiratory cell and molecular biology 20120501

• Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement.

  Pharmacology, biochemistry, and behavior 20120501

• Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: a practical access via Pd/C-Cu catalysis.

  Bioorganic & medicinal chemistry letters 20120401

• C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.

  Bioorganic & medicinal chemistry 20120401

• 4,4-Dimethyl-2-[3-nitro-2-phenyl-1-(phenyl-sulfan-yl)prop-yl]-4,5-dihydro-1,3-oxazole.

  Acta crystallographica. Section E, Structure reports online 20120401

• Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice.

  Neuropharmacology 20120301

• PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis.

  Translational psychiatry 20120301

• Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways.

  Life sciences 20120227

• Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

  Cell 20120203

• A re-assessment of a combinatorial treatment involving Schwann cell transplants and elevation of cyclic AMP on recovery of motor function following thoracic spinal cord injury in rats.

  Experimental neurology 20120201

• Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

  Psychopharmacology 20120201

• Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4.

  European journal of medicinal chemistry 20120201

• Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.

  PloS one 20120101

• Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization.

  International journal of nanomedicine 20120101

• Vinpocetine inhibits oligodendroglial precursor cell differentiation.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

• The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

  PloS one 20120101

• Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

  Journal of medicinal chemistry 20111208

• Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.

  Bioorganic & medicinal chemistry letters 20111201

• Inhibition of phosphodiesterase-4 decreases ethanol intake in mice.

  Psychopharmacology 20111101

• Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease.

  Human molecular genetics 20111101

• Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20111101

• NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.

  American journal of physiology. Lung cellular and molecular physiology 20111001

• Safety and efficacy of new 3,6-diaryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine analogs as potential phosphodiesterase-4 inhibitors in NIH-3T3 mouse fibroblastic cells.

  Chemical biology & drug design 20110901

• Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles.

  Muscle & nerve 20110901

• Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

  The Journal of pharmacology and experimental therapeutics 20110801

• A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI.

  Experimental neurology 20110701

• 2-(2-Fluorobenzamido)benzoate ethyl ester (EFB-1) inhibits superoxide production by human neutrophils and attenuates hemorrhagic shock-induced organ dysfunction in rats.

  Free radical biology & medicine 20110615

• Partially purified extract and viscolin from Viscum coloratum attenuate airway inflammation and eosinophil infiltration in ovalbumin-sensitized mice.

  Journal of ethnopharmacology 20110601

• Effect of phoshpodiesterase 4 (PDE4) inhibibtors on eotaxin expression in humen bronchial epithelial cells.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110601

• Epac-mediated cAMP-signalling in the mouse model of Rett Syndrome.

  Neuropharmacology 20110501

• Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20110401

• Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.

  The Journal of biological chemistry 20110304

• Anti-inflammatory properties of Septilin in lipopolysaccharide activated monocytes and macrophage.

  Immunopharmacology and immunotoxicology 20110301

• Effect of elevated intracellular cAMP levels on actomyosin contraction in bovine trabecular meshwork cells.

  Investigative ophthalmology & visual science 20110301

• Asymmetric synthesis of β-substituted γ-lactams via rhodium/diene-catalyzed 1,4-additions: application to the synthesis of (R)-baclofen and (R)-rolipram.

  Organic letters 20110218

• Soluble adenylyl cyclase mediates bicarbonate-dependent corneal endothelial cell protection.

  American journal of physiology. Cell physiology 20110201

• Beta-adrenergic stimulation contributes to maintenance of endothelial barrier functions under baseline conditions.

  Microcirculation (New York, N.Y. : 1994) 20110201

• Inhibition of ATP release from erythrocytes: a role for EPACs and PKC.

  Microcirculation (New York, N.Y. : 1994) 20110201

• PET of (R)-11C-rolipram binding to phosphodiesterase-4 is reproducible and sensitive to increased norepinephrine in the rat heart.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110201

• Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110105

• Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28.

  PloS one 20110101

• Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.

  Journal of biomedical science 20110101

• Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20110101

• PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.

  Current radiopharmaceuticals 20110101

• Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.

  Clinical hemorheology and microcirculation 20110101

• Improving the relaxing effect of terbutaline with phosphodiesterase inhibitors: studies on pregnant rat uteri in vitro.

  Life sciences 20101218

• Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils.

  The European respiratory journal 20101201

• Exposure of human seminal vesicle tissue to phosphodiesterase (PDE) inhibitors antagonizes the contraction induced by norepinephrine and increases production of cyclic nucleotides.

  Urology 20101201

• Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C.

  The Biochemical journal 20101115

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit.

  Genes & development 20101015

• Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.

  Journal of medicinal chemistry 20101014

• Enhanced expression of ATP-binding cassette transporter A1 in non-rafts decreases the sensitivity of vascular endothelial cells to Shiga toxin.

  Microbial pathogenesis 20101001

• p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways.

  Cellular signalling 20101001

• Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects.

  European journal of pharmacology 20100915

• Bronchodilatory effect of Acorus calamus (Linn.) is mediated through multiple pathways.

  Journal of ethnopharmacology 20100915

• Methylxanthine reversal of opioid-evoked inspiratory depression via phosphodiesterase-4 blockade.

  Respiratory physiology & neurobiology 20100731

• Function of cardiac beta1- and beta2-adrenoceptors of newborn piglets: role of phosphodiesterases PDE3 and PDE4.

  European journal of pharmacology 20100725

• Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats.

  Pancreas 20100701

• Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices.

  European journal of pharmacology 20100610

• Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100601

• Perivascular fluid cuffs decrease lung compliance by increasing tissue resistance.

  Critical care medicine 20100601

• The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species.

  European journal of pharmacology 20100510

• Type 4 phosphodiesterase plays different integrating roles in different cellular domains in pyramidal cortical neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100428

• Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors.

  European journal of pharmacology 20100425

• Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.

  International immunopharmacology 20100401

• Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20100401

• Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.

  Bioorganic & medicinal chemistry letters 20100401

• The ceramide-1-phosphate analogue PCERA-1 modulates tumour necrosis factor-alpha and interleukin-10 production in macrophages via the cAMP-PKA-CREB pathway in a GTP-dependent manner.

  Immunology 20100301

• Phosphodiesterase type 4 inhibition does not restore ocular dominance plasticity in a ferret model of fetal alcohol spectrum disorders.

  Alcoholism, clinical and experimental research 20100301

• Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia.

  European journal of pharmacology 20100210

• Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.

  Fundamental & clinical pharmacology 20100201

• Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats.

  Synapse (New York, N.Y.) 20100201

• A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

  Psychopharmacology 20100201

• Synaptic adaptations of CA1 pyramidal neurons induced by a highly effective combinational antidepressant therapy.

  Biological psychiatry 20100115

• The type IV phosphodiesterase inhibitor rolipram disturbs expression and extinction of conditioned fear in mice.

  Neuropharmacology 20100101

• Effects of rolipram on U46619-induced contraction and cyclic nucleotide content in the porcine coronary artery.

  Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20100101

• Various emetogens increase the secretion of salivary amylase in rats: a potential model in emesis research.

  Journal of pharmacological sciences 20100101

• Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

  Arthritis research & therapy 20100101

• Elevated cAMP opposes (TNF-alpha)-induced loss in the barrier integrity of corneal endothelium.

  Molecular vision 20100101

• The selective inhibition of type IV phosphodiesterase attenuates the severity of the acute pancreatitis in rats.

  Digestive diseases and sciences 20091201

• Evidence that corticotropin-releasing hormone modulates myometrial contractility during human pregnancy.

  Endocrinology 20091201

• Theophylline inhibits the differentiation of human monocyte into dendritic cell potentially via adenosine receptor antagonism.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20091201

• Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20091201

• Sleep deprivation impairs cAMP signalling in the hippocampus.

  Nature 20091022

• Effects of rolipram and diazepam on the adaptive changes induced by morphine withdrawal in the hypothalamic paraventricular nucleus.

  European journal of pharmacology 20091012

• Activity-based therapies to promote forelimb use after a cervical spinal cord injury.

  Journal of neurotrauma 20091001

• The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens.

  Psychopharmacology 20091001

• Accelerating axon growth to overcome limitations in functional recovery after peripheral nerve injury.

  Neurosurgery 20091001

• Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown.

  Journal of cellular physiology 20090901

• The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

  The Journal of pharmacology and experimental therapeutics 20090901

• Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.

  Peptides 20090901

• Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats.

  Respirology (Carlton, Vic.) 20090901

• In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.

  European journal of haematology 20090701

• Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.

  Bioorganic & medicinal chemistry letters 20090701

• Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.

  Pulmonary pharmacology & therapeutics 20090601

• PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.

  American journal of physiology. Lung cellular and molecular physiology 20090601

• The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release.

  British journal of pharmacology 20090601

• Involvement of phosphodiesterase 4 in beta-adrenoceptor agonist-induced amylase release in parotid acinar cells.

  Journal of oral science 20090601

• Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines.

  European journal of pharmacology 20090521

• Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis.

  Cellular signalling 20090501

• Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling.

  Physiological genomics 20090501

• Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

  Bioorganic & medicinal chemistry letters 20090415

• Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.

  Naunyn-Schmiedeberg's archives of pharmacology 20090401

• Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.

  Molecular psychiatry 20090401

• The type 4 phosphodiesterase inhibitors rolipram and YM976 facilitate recall of the weak version of the passive avoidance task in the day-old chick.

  Pharmacology, biochemistry, and behavior 20090401

• Semi-synthetic analogs of pinitol as potential inhibitors of TNF-alpha cytokine expression in human neutrophils.

  Bioorganic & medicinal chemistry letters 20090401

• Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury.

  Experimental neurology 20090401

• Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury.

  The journal of spinal cord medicine 20090401

• Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.

  Journal of medicinal chemistry 20090326

• PDE type-4 inhibition increases L-type Ca(2+) currents, action potential firing, and quantal size of exocytosis in mouse chromaffin cells.

  Pflugers Archiv : European journal of physiology 20090301

• Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.

  The European journal of neuroscience 20090301

• Reduced in vivo phosphodiesterase-4 response to acute noradrenaline challenge in diet-induced obese rats.

  Canadian journal of physiology and pharmacology 20090301

• ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes.

  Immunology letters 20090221

• Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor.

  Pharmacology, biochemistry, and behavior 20090201

• Utero-relaxant effect of PDE4-selective inhibitor alone and in simultaneous administration with beta2-mimetic on oxytocin-induced contractions in pregnant myometrium.

  The journal of obstetrics and gynaecology research 20090201

• Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.

  Glia 20090115

• Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.

  BJU international 20090101

• Increased particulate phosphodiesterase 4 in the prefrontal cortex supports 5-HT4 receptor-induced improvement of object recognition memory in the rat.

  Psychopharmacology 20090101

• Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte.

  International immunopharmacology 20090101

• Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart.

  British journal of pharmacology 20090101

• Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors.

  British journal of pharmacology 20090101

• Pharmacology of a novel, orally active PDE4 inhibitor.

  Pharmacology 20090101

• Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.

  Journal of medicinal chemistry 20081225

• Evidence that a protein kinase A substrate, small heat-shock protein 20, modulates myometrial relaxation in human pregnancy.

  Endocrinology 20081201

• Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.

  Experimental neurology 20081201

• Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081201

• mc1r Pathway regulation of zebrafish melanosome dispersion.

  Zebrafish 20081201

• Neuroenhancement: status quo and perspectives.

  European archives of psychiatry and clinical neuroscience 20081101

• Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues.

  Investigational new drugs 20081001

• Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats.

  Digestive diseases and sciences 20081001

• Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats.

  Urology 20081001

• Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.

  Investigative ophthalmology & visual science 20081001

• Optimization and validation of a reporter gene assay for screening of phosphodiesterase inhibitors in a high throughput system.

  Biotechnology journal 20081001

• Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.

  Journal of medicinal chemistry 20080925

• Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.

  Journal of dermatological science 20080901

• Critical role of PDE4D in beta2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts.

  The Journal of biological chemistry 20080815

• Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: effect of exogenous nitric oxide.

  Acta bio-medica : Atenei Parmensis 20080801

• Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.

  Journal of medicinal chemistry 20080724

• Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.

  Bioorganic & medicinal chemistry letters 20080715

• Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients.

  AIDS research and human retroviruses 20080701

• Prolonged heterologous beta2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction.

  American journal of physiology. Lung cellular and molecular physiology 20080601

• cAMP induced Rac 1-mediated cytoskeletal reorganization in microvascular endothelium.

  Histochemistry and cell biology 20080601

• Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.

  Neurobiology of disease 20080601

• Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats.

  European journal of pharmacology 20080531

• Mechanisms of the relaxant effect of vardenafil in rat penile arteries.

  European journal of pharmacology 20080531

• Epi-cinchona based thiourea organocatalyst family as an efficient asymmetric Michael addition promoter: enantioselective conjugate addition of nitroalkanes to chalcones and alpha,beta-unsaturated N-acylpyrroles.

  The Journal of organic chemistry 20080502

• Synthesis, anti-bacterial, anti-asthmatic and anti-diabetic activities of novel N-substituted-2-(4-phenylethynyl-phenyl)-1H-benzimidazoles and N-substituted 2[4-(4,4-dimethyl-thiochroman-6-yl-ethynyl)-phenyl)-1H-benzimidazoles.

  European journal of medicinal chemistry 20080501

• PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.

  Cellular signalling 20080501

• Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

  British journal of pharmacology 20080501

• Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.

  Experimental neurology 20080501

• Organocatalytic asymmetric total synthesis of (R)-rolipram and formal synthesis of (3S,4R)-paroxetine.

  Organic letters 20080403

• Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats.

  Experimental neurology 20080401

• Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats.

  Biochimica et biophysica acta 20080401

• PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.

  European journal of pharmacology 20080317

• Rhodanine derivatives as novel inhibitors of PDE4.

  Bioorganic & medicinal chemistry letters 20080315

• Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques.

  Psychopharmacology 20080301

• Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.

  The European respiratory journal 20080301

• Epac/Rap1 pathway regulates microvascular hyperpermeability induced by PAF in rat mesentery.

  American journal of physiology. Heart and circulatory physiology 20080301

• Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.

  Urology 20080301

• Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.

  Bioorganic & medicinal chemistry letters 20080215

• Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.

  British journal of pharmacology 20080201

• Phosphodiesterase inhibitors--are they potential neuroleptic drugs?

  Behavioural brain research 20080125

• Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.

  Pharmacology 20080101

• The role of VASP in regulation of cAMP- and Rac 1-mediated endothelial barrier stabilization.

  American journal of physiology. Cell physiology 20080101

• Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol.

  Pulmonary pharmacology & therapeutics 20080101

• Protein kinase C- and reactive oxygen species-dependent stimulation of intracellular cAMP in human eosinophils. The role of extracellular signal-regulated protein kinases.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20080101

• Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.

  PloS one 20080101

• Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.

  Critical care (London, England) 20080101

• Microtubule motors regulate ISOC activation necessary to increase endothelial cell permeability.

  The Journal of biological chemistry 20071130

• Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.

  European journal of pharmacology 20071114

• Rh-catalyzed asymmetric hydrogenation of gamma-phthalimido-substituted alpha,beta-unsaturated carboxylic acid esters: an efficient enantioselective synthesis of beta-aryl-gamma-amino acids.

  Organic letters 20071108

• Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat.

  Journal of cardiovascular pharmacology 20071001

• Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart.

  European journal of pharmacology 20070910

• [Recent progress in basic research concerning the management of benign prostatic hyperplasia].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20070901

• High-performance liquid chromatographic separation of rolipram, bupivacaine and omeprazole using a tartardiamide-based stationary phase influence of flow rate and temperature on the enantioseparation.

  Journal of chromatography. A 20070824

• Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

• PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).

  The Journal of pharmacology and experimental therapeutics 20070801

• The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.

  British journal of pharmacology 20070801

• Effect of sildenafil and rolipram on adrenergic responses in isolated human and monkey corpus cavernosum.

  European urology 20070701

• Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors.

  Urology 20070701

• The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat.

  Psychopharmacology 20070601

• Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

  Psychopharmacology 20070601

• Effects of stimulation of adenosine A2A receptors on lipopolysaccharide-induced production of reactive oxygen species by equine neutrophils.

  American journal of veterinary research 20070601

• Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.

  Cancer research 20070601

• Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.

  Journal of enzyme inhibition and medicinal chemistry 20070601

• Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.

  The Journal of biological chemistry 20070525

• Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling.

  Toxicology and applied pharmacology 20070515

• The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia.

  Stroke 20070501

• A reporter gene assay for screening of PDE4 subtype selective inhibitors.

  Biochemical and biophysical research communications 20070427

• Elevated cAMP levels reverse Brucella melitensis-induced lipid peroxidation and stimulate IL-10 transcription in rats.

  Research in veterinary science 20070401

• Alterations in proteoglycan synthesis selectively impair FSH-induced particulate cAMP-phosphodiesterase 4 (PDE4) activation in immature rat Sertoli cells.

  Biochimica et biophysica acta 20070401

• The effects of both noradrenaline and CGP12177, mediated through human beta1 -adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20070401

• Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability.

  Archives of pharmacal research 20070401

• Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP.

  The Journal of biological chemistry 20070323

• Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.

  European journal of pharmacology 20070315

• Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.

  European journal of pharmacology 20070308

• Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.

  European urology 20070301

• Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.

  Neurobiology of disease 20070201

• SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

  Journal of medicinal chemistry 20070125

• PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation.

  Journal of immunology (Baltimore, Md. : 1950) 20070115

• Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

  Neuroscience 20070105

• Regulation of luteinizing hormone receptor mRNA expression by a specific RNA binding protein in the ovary.

  Molecular and cellular endocrinology 20070102

• Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.

  Pulmonary pharmacology & therapeutics 20070101

• Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells.

  American journal of physiology. Cell physiology 20070101

• Preclinical assessment of curcumin as a potential therapy for B-CLL.

  American journal of hematology 20070101

• Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells.

  Journal of the American Society of Nephrology : JASN 20070101

• Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.

  Journal of applied toxicology : JAT 20070101

• In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.

  Nuclear medicine and biology 20070101

• Antagonism of IL-4 signaling by a phosphodiesterase-4 inhibitor, rolipram, in human T cells.

  International archives of allergy and immunology 20070101

• Role of protein kinase C in substance P-induced synaptic depression in the nucleus accumbens in vitro.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20070101

• Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.

  Immunological investigations 20070101

• Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.

  Journal of musculoskeletal & neuronal interactions 20070101

• Hormonal regulation of the contractile vacuole in Amoeba proteus: the role of cyclic nucleotide phosphodiesterases.

  Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections 20070101

• The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures.

  Respiratory research 20070101

• Cilostamide potentiates more the positive inotropic effects of (-)-adrenaline through beta(2)-adrenoceptors than the effects of (-)-noradrenaline through beta (1)-adrenoceptors in human atrial myocardium.

  Naunyn-Schmiedeberg's archives of pharmacology 20061201

• High sensitivity to neuromodulator-activated signaling pathways at physiological [K+] of confocally imaged respiratory center neurons in on-line-calibrated newborn rat brainstem slices.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20061115

• Cyclic AMP-mediated regulation of the resting membrane potential in myelin-forming oligodendrocytes in the isolated intact rat optic nerve.

  Experimental neurology 20061101

• Delayed Nogo receptor therapy improves recovery from spinal cord contusion.

  Annals of neurology 20061101

• Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons.

  Molecular and cellular neurosciences 20061101

• Modulation of melatonin receptors and G-protein function by microtubules.

  Journal of pineal research 20061101

• Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.

  Life sciences 20061012

• Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds.

  Behavioural brain research 20061002

• Synergistic effects of cAMP-dependent signalling pathways and IL-1 on IL-6 production by H19-7/IGF-IR neuronal cells.

  Cellular signalling 20061001

• Salbutamol inhibits trypsin-mediated production of CXCL8 by keratinocytes.

  Cytokine 20061001

• Neuronal and smooth muscle receptors involved in the PACAP- and VIP-induced relaxations of the pig urinary bladder neck.

  British journal of pharmacology 20060901

• Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice.

  Investigative radiology 20060901

• Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20060901

• Lack of cyclic AMP-specific phosphodiesterase 4 activation during naloxone-precipitated morphine withdrawal in rats.

  Neuroscience letters 20060814

• Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice.

  FEBS letters 20060724

• Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.

  Biochemical and biophysical research communications 20060721

• Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors.

  Life sciences 20060717

• Hydraulic conductance of pulmonary microvascular and macrovascular endothelial cell monolayers.

  American journal of physiology. Lung cellular and molecular physiology 20060701

• Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram.

  Brain research 20060622

• Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart.

  Life sciences 20060620

• Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

  Psychopharmacology 20060601

• ANP-mediated cGMP signaling and phosphodiesterase inhibition in the rat cervical spinal cord.

  Journal of chemical neuroanatomy 20060601

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Activation of the adenylyl cyclase/protein kinase A pathway facilitates neural release of beta-nicotinamide adenine dinucleotide in canine mesenteric artery.

  European journal of pharmacology 20060424

• Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells.

  American journal of physiology. Lung cellular and molecular physiology 20060401

• Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action.

  Neurobiology of learning and memory 20060301

• Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes.

  The Biochemical journal 20060301

• Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells.

  Experimental biology and medicine (Maywood, N.J.) 20060301

• Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.

  European journal of pharmacology 20060217

• Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats.

  Archives of toxicology 20060201

• Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.

  The Journal of pharmacology and experimental therapeutics 20060201

• Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells.

  British journal of pharmacology 20060201

• Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation.

  The Journal of biological chemistry 20060113

• TcPDE4, a novel membrane-associated cAMP-specific phosphodiesterase from Trypanosoma cruzi.

  Molecular and biochemical parasitology 20060101

• An investigation into the effect of the type IV phosphodiesterase inhibitor rolipram in the modulation of glutamate release from rat prefrontocortical nerve terminals.

  Synapse (New York, N.Y.) 20060101

• Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

  Pulmonary pharmacology & therapeutics 20060101

• Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle.

  British journal of pharmacology 20060101

• Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.

  Current medicinal chemistry 20060101

• [Effect of phosphodiestrase 4 inhibitor (rolipram) on experimental allergic asthma-guinea pig model].

  Pneumonologia i alergologia polska 20060101

• Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type IV-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20051116

• Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

  Neurobiology of disease 20051101

• Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

  Psychopharmacology 20051001

• The pivotal role of cytokines in muscle wasting during cancer.

  The international journal of biochemistry & cell biology 20051001

• Pharmacological studies on mechanisms of aminophylline-induced seizures in rats.

  Indian journal of experimental biology 20051001

• Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050928

• An Aplysia type 4 phosphodiesterase homolog localizes at the presynaptic terminals of Aplysia neuron and regulates synaptic facilitation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050928

• In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region.

  Cellular signalling 20050901

• Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation.

  Molecular reproduction and development 20050801

• Effects of rolipram on induction of action potential bursts in central snail neurons.

  Experimental neurology 20050801

• Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of mesenteric postcapillary fluid leak.

  The Journal of trauma 20050801

• [Evaluation methods for the discriminative stimulus and possible mechanisms of discriminative stimulus effects of methamphetamine in the rat].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20050701

• Type 4 phosphodiesterase inhibition impairs detection of low odor concentrations in mice.

  Behavioural brain research 20050620

• Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes.

  Journal of immunology (Baltimore, Md. : 1950) 20050615

• Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.

  Biochemistry 20050614

• Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in rats.

  Digestive diseases and sciences 20050601

• Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.

  European journal of pharmacology 20050509

• Essential role of a Ca2+-selective, store-operated current (ISOC) in endothelial cell permeability: determinants of the vascular leak site.

  Circulation research 20050429

• Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium.

  American journal of physiology. Heart and circulatory physiology 20050401

• Airway function and reactivity, leukocyte influx and nitric oxide after inoculation with parainfluenza-3 virus: effects of dexamethasone or rolipram.

  International immunopharmacology 20050401

• Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.

  Bioorganic & medicinal chemistry letters 20050401

• Rolipram attenuates MK-801-induced deficits in latent inhibition.

  Behavioral neuroscience 20050401

• Inhibition of mast cell histamine release by specific phosphodiesterase inhibitors.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20050401

• Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium.

  The Journal of biological chemistry 20050304

• Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.

  Medicinal research reviews 20050301

• Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.

  Yonsei medical journal 20050227

• 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.

  Journal of medicinal chemistry 20050224

• Synthesis of 4-aryl-2-pyrrolidones and beta-aryl-gamma-amino-butyric acid (GABA) analogues by Heck arylation of 3-pyrrolines with arenediazonium tetrafluoroborates. Synthesis of (+/-)-rolipram on a multigram scale and chromatographic resolution by semipreparative chiral simulated moving bed chromatography.

  The Journal of organic chemistry 20050204

• Effect of rolipram on relative 14C-deoxyglucose uptake in inflammatory lesions and skeletal muscle.

  European journal of nuclear medicine and molecular imaging 20050201

• Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.

  Biochemical pharmacology 20050201

• A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells.

  Journal of immunology (Baltimore, Md. : 1950) 20050115

• The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.

  Pulmonary pharmacology & therapeutics 20050101

• Specific type IV phosphodiesterase inhibitor ameliorates thioacetamide-induced liver injury in rats.

  Journal of gastroenterology and hepatology 20050101

• Rolipram, salbutamol and prostaglandin E2 suppress TNFalpha release from human monocytes by activating Type II cAMP-dependent protein kinase.

  Pulmonary pharmacology & therapeutics 20050101

• A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy.

  Nephron. Experimental nephrology 20050101

• Crystallization of cyclic nucleotide phosphodiesterases.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation.

  Respiratory research 20050101

• Potentiation and prolongation of long-term odor memory in neonate rats using a phosphodiesterase inhibitor.

  Neuroscience 20050101

• An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.

  The Journal of infectious diseases 20041215

• Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.

  Molecular pharmacology 20041201

• Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes.

  Cellular signalling 20041201

• Chlamydophila pneumoniae induces p44/p42 mitogen-activated protein kinase activation in human fibroblasts through Toll-like receptor 4.

  Journal of medical microbiology 20041201

• Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.

  Journal of enzyme inhibition and medicinal chemistry 20041201

• Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.

  Life sciences 20041119

• The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types.

  Endocrinology 20041101

• cAMP response element-binding protein activation in ligation preconditioning in neonatal brain.

  Annals of neurology 20041101

• Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae.

  Journal of cardiovascular pharmacology 20041101

• Persistent accumulation of calcium/calmodulin-dependent protein kinase II in dendritic spines after induction of NMDA receptor-dependent chemical long-term potentiation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20041020

• Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C.

  European journal of pharmacology 20041006

• Effect of specific phosphodiesterase isoenzyme inhibitors during in vitro maturation of bovine oocytes on meiotic and developmental capacity.

  Biology of reproduction 20041001

• Altered activities of cyclic nucleotide phosphodiesterases and soluble guanylyl cyclase in cultured RFL-6 cells.

  The international journal of biochemistry & cell biology 20041001

• Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.

  Bioorganic & medicinal chemistry 20041001

• Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium.

  Naunyn-Schmiedeberg's archives of pharmacology 20041001

• The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task.

  Behavioural brain research 20040923

• Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.

  European journal of pharmacology 20040913

• The effect of the indomethacin on phosphodiesterase inhibitors mediated responses in isolated trachea preparations.

  Prostaglandins, leukotrienes, and essential fatty acids 20040901

• Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.

  British journal of pharmacology 20040901

• Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram.

  Acta pharmacologica Sinica 20040901

• The type IV-specific phosphodiesterase inhibitor rolipram and its effect on hippocampal long-term potentiation and synaptic tagging.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040901

• Cyclic nucleotide-dependent phosphodiesterases (PDEI) inhibition by muscarinic antagonists in bovine tracheal smooth muscle.

  Biochemical pharmacology 20040815

• The synergistic effect of adenosine A2A receptors agonist, type IV phosphodiestease inhibitor and ATP-sensitive K channels activation on free radicals production and aggregation of human polymorphoneuclear leukocytes.

  Pharmacological research 20040801

• Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.

  Biochemical pharmacology 20040801

• Repetitive exposures to nicotine induce a hyper-responsiveness via the cAMP/PKA/CREB signal pathway in Drosophila.

  Journal of neurobiology 20040801

• Paradoxical cAMP-induced lung endothelial hyperpermeability revealed by Pseudomonas aeruginosa ExoY.

  Circulation research 20040723

• Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.

  Life sciences 20040702

• Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.

  The Journal of allergy and clinical immunology 20040701

• Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.

  Journal of pharmacological sciences 20040701

• Identification of purine inhibitors of phosphodiesterase 7 (PDE7).

  Bioorganic & medicinal chemistry letters 20040607

• Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes.

  International immunopharmacology 20040601

• cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury.

  Nature medicine 20040601

• PDE4 inhibitors in COPD--a more selective approach to treatment.

  Respiratory medicine 20040601

• Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.

  The Journal of pharmacy and pharmacology 20040601

• Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent.

  Journal of neurophysiology 20040501

• Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase inhibitor gene to BEAS-2B epithelial cells abolishes the anti-inflammatory effects of rolipram, salbutamol, and prostaglandin E2: a comparison with H-89.

  The Journal of pharmacology and experimental therapeutics 20040501

• Augmentation of lipolysis in adipocytes from fed rats, but not from starved rats, by inhibition of rolipram-sensitive phosphodiesterase 4.

  Archives of biochemistry and biophysics 20040501

• Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.

  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20040501

• PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration.

  Journal of cell science 20040501

• The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice.

  The European journal of neuroscience 20040501

• Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.

  Blood 20040401

• Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

  Journal of molecular biology 20040319

• Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxin-induced cytokine expression in bovine alveolar macrophages.

  Microbial pathogenesis 20040301

• Synthesis and biological evaluation of neutrophilic inflammation inhibitors.

  Farmaco (Societa chimica italiana : 1989) 20040301

• [Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats].

  Nihon rinsho. Japanese journal of clinical medicine 20040301

• Association between inflammation and nigral neuronal damage following striatal excitotoxic lesion.

  Brain research 20040213

• Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.

  Biology of reproduction 20040201

• Antidiuretic hormone resistance in the neonatal cortical collecting tubule is mediated in part by elevated phosphodiesterase activity.

  American journal of physiology. Renal physiology 20040201

• Inhibitory effects of group II mGluR-related drugs on memory performance in mice.

  Physiology & behavior 20040201

• Rho GTPases and phosphoinositide 3-kinase organize formation of branched dendrites.

  The Journal of biological chemistry 20040102

• Heterogeneity of neuronal and smooth muscle receptors involved in the VIP- and PACAP-induced relaxations of the pig intravesical ureter.

  British journal of pharmacology 20040101

• Impact of cAMP on the T-cell response to type II collagen.

  Immunology 20040101

• Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells.

  The Journal of clinical endocrinology and metabolism 20040101

• Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20040101

• Development of an in vitro model for vascular injury with human endothelial cells.

  ALTEX 20040101

• Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils.

  Pulmonary pharmacology & therapeutics 20040101

• Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications.

  Neuroscience 20040101

• Phosphoinositide 3-kinase is involved in Xenopus and Labrus melanophore aggregation.

  Cellular signalling 20031201

• Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats.

  Brain research 20031121

• Effect of two phenanthrene alkaloids on angiotensin II-induced leukocyte-endothelial cell interactions in vivo.

  British journal of pharmacology 20031101

• Lidocaine enhances Galphai protein function.

  Anesthesiology 20031101

• Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2.

  Cardiovascular research 20031101

• Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.

  Cellular signalling 20031001

• Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function.

  The Journal of pharmacology and experimental therapeutics 20031001

• PDE4D plays a critical role in the control of airway smooth muscle contraction.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031001

• Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.

  American journal of respiratory cell and molecular biology 20030901

• Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7.

  Cellular signalling 20030901

• Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.

  The Journal of biological chemistry 20030829

• Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.

  The Journal of allergy and clinical immunology 20030801

• Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.

  Bioorganic & medicinal chemistry letters 20030721

• Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.

  Bioorganic & medicinal chemistry letters 20030721

• Regulation of the cAMP-elevating effects of isoproterenol and forskolin in cardiac myocytes by treatments that cause increases in cAMP.

  Biochemical and biophysical research communications 20030718

• Effect of phosphodiesterase type 4 on circadian clock gene Per1 transcription.

  Biochemical and biophysical research communications 20030704

• Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium.

  Pharmacology & toxicology 20030701

• Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.

  Structure (London, England : 1993) 20030701

• Gamma-lactam synthesis via C-H insertion: elaboration of N-benzyl protecting groups for high regioselectivity toward the total synthesis of rolipram.

  Organic letters 20030626

• Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils.

  Intensive care medicine 20030601

• Theophylline attenuates the adhesion of eosinophils to endothelial cells.

  International archives of allergy and immunology 20030601

• Histamine up-regulates phosphodiesterase IV activity in U-937 cells through H2 receptor stimulation and cAMP increase.

  Medical science monitor : international medical journal of experimental and clinical research 20030601

• PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.

  Blood 20030515

• Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.

  The Journal of pharmacology and experimental therapeutics 20030501

• Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism.

  Carcinogenesis 20030501

• Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats.

  Pathophysiology : the official journal of the International Society for Pathophysiology 20030501

• Effect of rolipram on muscarinic acetylcholine receptor binding in the intact mouse brain.

  Journal of neural transmission (Vienna, Austria : 1996) 20030401

• In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.

  Journal of veterinary pharmacology and therapeutics 20030401

• [Physiopathology of COPD: choosing the right therapeutic targets].

  Revue de pneumologie clinique 20030401

• Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion.

  Transplantation 20030327

• Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.

  European journal of anaesthesiology 20030301

• Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.

  British journal of pharmacology 20030301

• Involvement of cyclic AMP-mediated pathway in neural release of noradrenaline in canine isolated mesenteric artery and vein.

  Cardiovascular research 20030101

• Effect of the phosphodiesterase 4 inhibitor, rolipram, on retinoic acid-increased alkaline phosphatase activity in the mouse fibroblastic C3H10T1/2 cell line.

  Archives of oral biology 20030101

• Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.

  Pulmonary pharmacology & therapeutics 20030101

• Later developments: molecular keys to age-related memory impairment.

  Alzheimer disease and associated disorders 20030101

• Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.

  Arthritis research & therapy 20030101

• AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.

  American journal of physiology. Renal physiology 20021201

• Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors.

  Investigative radiology 20021201

• Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20021115

• Development of a catalytic enantioselective conjugate addition of 1,3-dicarbonyl compounds to nitroalkenes for the synthesis of endothelin-A antagonist ABT-546. Scope, mechanism, and further application to the synthesis of the antidepressant rolipram.

  Journal of the American Chemical Society 20021106

• Inhibition of human phosphodiesterase 4A expressed in yeast cell GL62 by theophylline, rolipram, and acetamide-45.

  Acta pharmacologica Sinica 20021101

• Enhancement of the relative uptake of 18F-FDG in mouse fibrosarcoma by rolipram.

  Annals of nuclear medicine 20021101

• Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20021001

• Cyclic AMP-mediated modulation of epileptiform afterdischarge generation in rat hippocampal slices.

  Brain research 20020913

• The effects of cAMP modulation upon the adhesion and respiratory burst activity of immune complex-stimulated equine neutrophils.

  Veterinary immunology and immunopathology 20020906

• A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.

  Bioorganic & medicinal chemistry letters 20020902

• Rolipram depresses [(3)H]2-deoxyglucose uptake in mouse brain and heart in vivo.

  European journal of nuclear medicine and molecular imaging 20020901

• Effects of rolipram on in vivo dopamine receptor binding.

  Journal of neural transmission (Vienna, Austria : 1996) 20020901

• Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.

  Cardiovascular drugs and therapy 20020901

• Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.

  Cytokine 20020821

• Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model.

  Transplantation 20020815

• Phosphodiesterase 3 inhibitors selectively block the spontaneous resumption of meiosis by macaque oocytes in vitro.

  Human reproduction (Oxford, England) 20020801

• Changes in phosphodiesterase activity in the developing rat submandibular gland.

  Archives of oral biology 20020801

• Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.

  The Journal of pharmacology and experimental therapeutics 20020701

• Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.

  The Journal of pharmacology and experimental therapeutics 20020701

• Airway function, oedema, cell infiltration and nitric oxide generation in conscious ozone-exposed guinea-pigs: effects of dexamethasone and rolipram.

  British journal of pharmacology 20020701

• Crystal structure of 5-t-butoxycarbonyl-1-benzoyl-2-pyrrolidinone, an intermediate in the synthesis of (-)-rolipram.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20020701

• 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.

  Bioorganic & medicinal chemistry letters 20020617

• Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.

  Journal of medicinal chemistry 20020606

• Phosphodiesterase type 4 inhibitor reduces the retention of polymorphonuclear leukocytes in the lung.

  American journal of physiology. Lung cellular and molecular physiology 20020601

• Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).

  British journal of pharmacology 20020601

• DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer.

  Naunyn-Schmiedeberg's archives of pharmacology 20020601

• Relaxation induced by milrinone and rolipram in human penile arteries and veins.

  European journal of pharmacology 20020524

• Functional plasticity of cyclic AMP hydrolysis in rat adenohypophysial corticotroph cells.

  Cellular signalling 20020501

• Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: role of phosphodiesterase and protein kinase C.

  The Journal of pharmacology and experimental therapeutics 20020501

• Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.

  Blood 20020501

• Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cytosolic calcium.

  British journal of pharmacology 20020501

• Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.

  Naunyn-Schmiedeberg's archives of pharmacology 20020401

• Endotoxin potentiation of trichothecene-induced lymphocyte apoptosis is mediated by up-regulation of glucocorticoids.

  Toxicology and applied pharmacology 20020401

• Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro.

  Diseases of the colon and rectum 20020401

• Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization.

  American journal of physiology. Heart and circulatory physiology 20020301

• Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.

  Bioorganic & medicinal chemistry letters 20020225

• Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).

  Biochemical pharmacology 20020215

• Involvement of phosphodiesterase isozymes in osteoblastic differentiation.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020201

• The effects of intravenous anesthetics and lidocaine on proliferation of cultured type II pneumocytes and lung fibroblasts.

  Anesthesia and analgesia 20020201

• Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020201

• Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor.

  Biological & pharmaceutical bulletin 20020201

• Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux.

  Biochemical and biophysical research communications 20020118

• Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.

  Bioorganic & medicinal chemistry letters 20020107

• Cyclic adenosine monophosphate-dependent vascular responses to purinergic agonists adenosine triphosphate and uridine triphosphate in the anesthetized mouse.

  Journal of cardiovascular pharmacology 20020101

• Peptidergic and nitrergic inhibitory neurotransmissions in the hamster jejunum: regulation of vasoactive intestinal peptide release by nitric oxide.

  Neuroscience 20020101

• Participation of peripheral and spinal phosphodiesterases 4 and 5 in inflammatory pain.

  Proceedings of the Western Pharmacology Society 20020101

• Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain.

  Synapse (New York, N.Y.) 20011215

• Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.

  Clinical and experimental immunology 20011201

• cAMP-elevating agents suppress dendritic cell function.

  Journal of leukocyte biology 20011201

• Relaxation and modulation of cyclic AMP production in response to atrial natriuretic peptides in guinea pig tracheal smooth muscle.

  European journal of pharmacology 20011102

• Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.

  The Journal of pharmacology and experimental therapeutics 20011101

• Differential phosphodiesterase activity contributes to restrictive endothelial barrier function during angiogenesis.

  Microvascular research 20011101

• The kinetics, function, and regulation of P-selectin expressed by human brain microvessel endothelial cells in primary culture.

  Microvascular research 20011101

• Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.

  British journal of pharmacology 20011101

• Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.

  Psychopharmacology 20011101

• Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

  Leukemia 20011001

• Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.

  British journal of pharmacology 20010901

• Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.

  British journal of pharmacology 20010901

• Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.

  Biochemistry 20010828

• Additive effects of intra-accumbens infusion of the cAMP-specific phosphodiesterase inhibitor, rolipram and cocaine on brain stimulation reward.

  Life sciences 20010824

• First highly regio- and diastereoselective [3+2] cycloaddition of chiral nonracemic Fischer carbene complexes with azomethine ylides: an enantioselective synthesis of (+)-rolipram.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20010817

• Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A.

  Journal of immunology (Baltimore, Md. : 1950) 20010815

• Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.

  Journal of medicinal chemistry 20010802

• Systemic and topical drug administration in the pig ureter: effect of phosphodiesterase inhibitors alpha1, beta and beta2-adrenergic receptor agonists and antagonists on the frequency and amplitude of ureteral contractions.

  The Journal of urology 20010801

• Diazepam increases the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a cyclic AMP-dependent mechanism.

  British journal of pharmacology 20010801

• Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production.

  Laboratory investigation; a journal of technical methods and pathology 20010801

• Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes.

  Chemical & pharmaceutical bulletin 20010801

• Differential inhibition of equine neutrophil function by phosphodiesterase inhibitors.

  Journal of veterinary pharmacology and therapeutics 20010801

• Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: effect of rolipram and dexamethasone.

  The Journal of pharmacology and experimental therapeutics 20010701

• Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.

  British journal of pharmacology 20010701

• Vasodilator responses to ATP and UTP are cAMP dependent in the mesenteric vascular bed of the cat.

  Journal of cardiovascular pharmacology and therapeutics 20010701

• Noradrenaline modulates oyster hemocyte phagocytosis via a beta-adrenergic receptor-cAMP signaling pathway.

  General and comparative endocrinology 20010601

• Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition.

  Kidney international 20010601

• Modulation of thapsigargin-induced calcium mobilisation by cyclic AMP-elevating agents in human lymphocytes is insensitive to the action of the protein kinase A inhibitor H-89.

  Cellular signalling 20010601

• Maintenance of cAMP in non-heart-beating donor lungs reduces ischemia-reperfusion injury.

  American journal of respiratory and critical care medicine 20010601

• Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources.

  Naunyn-Schmiedeberg's archives of pharmacology 20010601

• Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.

  Mediators of inflammation 20010601

• Rolipram reduces excitotoxic neuronal damage.

  Neuroreport 20010525

• Characterization of r-[11C]rolipram for PET imaging of phosphodieterase-4: in vivo binding, metabolism, and dosimetry studies in rats.

  Nuclear medicine and biology 20010501

• Design of rolipram-loaded nanoparticles: comparison of two preparation methods.

  Journal of controlled release : official journal of the Controlled Release Society 20010428

• Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.

  European journal of pharmacology 20010406

• Effects of phosphodiesterase inhibitors on hypoxic pulmonary vasoconstriction. Influence of K(+) channels and nitric oxide.

  European journal of pharmacology 20010406

• Type IV phosphodiesterase inhibitor suppresses insulin-dependent myocardial glucose uptake.

  Clinical and experimental pharmacology & physiology 20010401

• Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.

  Cellular signalling 20010401

• Buchu (Agathosma betulina and A. crenulata, Rutaceae) essential oils: their pharmacological action on guinea-pig ileum and antimicrobial activity on microorganisms.

  The Journal of pharmacy and pharmacology 20010401

• Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.

  Biochimica et biophysica acta 20010319

• Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.

  Bioorganic & medicinal chemistry letters 20010312

• Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor.

  British journal of pharmacology 20010301

• Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.

  Cellular signalling 20010301

• The influence of phosphodiesterase inhibitor, rolipram, on hemodynamics in lipopolysaccharide-treated rats.

  Japanese journal of pharmacology 20010301

• Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.

  Bioorganic & medicinal chemistry letters 20010226

• Inflammation contributes to the postponed ischemic neuronal damage following treatment with a glutamate antagonist in rats.

  Neuroscience letters 20010202

• The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.

  Clinical immunology (Orlando, Fla.) 20010201

• Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.

  Bioorganic & medicinal chemistry letters 20010108

• A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice.

  Behavioural brain research 20010108

• PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.

  Neuropharmacology 20010101

• Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010101

• Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.

  American journal of respiratory and critical care medicine 20010101

• [Suppression of synthesis of tumor necrosis factor].

  Der Internist 20010101

• Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.

  Pulmonary pharmacology & therapeutics 20010101

• [Inhibition of uterine contractions: new in vitro pharmacological approaches on the pregnant human myometrium].

  Therapie 20010101

• The antidepressant and antiinflammatory effects of rolipram in the central nervous system.

  CNS drug reviews 20010101

• Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.

  Inflammation 20000801

• Use of an activation-specific probe to show that Rap1A and Rap1B display different sensitivities to activation by forskolin in rat1 cells.

  FEBS letters 20000721

• beta-Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils.

  Naunyn-Schmiedeberg's archives of pharmacology 20000401

• Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia.

  British journal of pharmacology 19990601

• The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform.

  The Journal of biological chemistry 19990521

• SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

  The Journal of pharmacology and experimental therapeutics 19981101

• Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors.

  The Journal of allergy and clinical immunology 19981101

• Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism.

  British journal of pharmacology 19981101

• Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT.

  Journal of virology 19980601

• SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

  The Journal of pharmacology and experimental therapeutics 19980101

• CDP840: a novel inhibitor of PDE-4.

  Cell biochemistry and biophysics 19980101

• Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition.

  The Journal of clinical investigation 19971001

• Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.

  Biochemical and biophysical research communications 19970519

• The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

  British journal of pharmacology 19961101

• Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 19960401

• Delayed sympathectomy after a prolonged hyperalgesia results in a subsequent enhanced acute hyperalgesic response.

  Neuroscience 19960401

• Action of cAMP on expression and release of adhesion molecules in human endothelial cells.

  The American journal of physiology 19960301

• Dipyridamole enhances interleukin-1beta-stimulated nitric oxide production by cultured rat vascular smooth muscle cells.

  European journal of pharmacology 19960205

• Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.

  Cellular signalling 19960201

• Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.

  AIDS (London, England) 19951001

• Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways.

  Japanese journal of pharmacology 19950201

• Multiple second messenger systems act sequentially to mediate rolipram-induced prolongation of prostaglandin E2-induced mechanical hyperalgesia in the rat.

  Neuroscience 19950201

• Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin.

  Peptides 19950101

• Central and peripheral minocycline suppresses motor activity in rats.

  Pharmacology, biochemistry, and behavior 19930201

• Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia.

  Neuroscience 19910101

• Adenosine receptor antagonism accounts for the seizure-prolonging effects of aminophylline.

  Pharmacology, biochemistry, and behavior 19900801

• Caffeine and panic attacks.

  The British journal of psychiatry : the journal of mental science 19870501